Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Up to 20% of all non-small cell lung cancer patients harbor tumor specific driver mutations that are effectively treated with tyrosine kinase inhibitors. However, for the rare EGFR deletion-insertion mutation of exon 18, there is very little evidence regarding the effectiveness of tyrosine kinase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cekay, Michael, Arndt, Philipp F., Dumitrascu, Rio, Savai, Rajkumar, Braeuninger, Andreas, Gattenloehner, Stefan, Steiner, Dagmar, Roller, Fritz, Tello, Khodr, Hattar, Katja, Seeger, Werner, Sibelius, Ulf, Grimminger, Friedrich, Eul, Bastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466799/
https://www.ncbi.nlm.nih.gov/pubmed/37655099
http://dx.doi.org/10.3389/fonc.2023.1182391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466799/
https://www.ncbi.nlm.nih.gov/pubmed/37655099
http://dx.doi.org/10.3389/fonc.2023.1182391

Ejemplares similares